Author

M.S. Steiner

Observed names: MS Steiner, Steiner, M.S.

Institution: Veru Inc. (United States)

Observed institutions: GTx (United States), Vanderbilt University, Veru Inc. (United States)

OpenAlex ID: A5083200461

Transforming growth factor-? and prostate cancer

1995 · M.S. Steiner · World Journal of Urology · 28

An overview on selective androgen receptor modulators: Focus on enobosarm

2013 · Jones, A., Coss, C.C., et al. · Drugs of the Future · 5

Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer

2013 · JT Dalton, R Narayanan, et al. · Cancer Research · 4

206TiP Randomized, multicenter, international phase III ARTEST study to evaluate enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who previously received an estrogen-blocking agent and a CDK 4/6 inhibitor

2022 · A. Brufsky, H. Linden, et al. · Annals of Oncology · 1

1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent

2022 · M.C. Markowski, M. Eisenberger, et al. · Annals of Oncology

Sabizabulin has both cytotoxic and cytostatic activity in Phase 1b/2 clinical of men with metastatic castration resistant prostate cancer who progressed on androgen receptor targeting agents

2022 · M. Markowski, M. Eisenberger, et al. · European Urology

VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1

2019 · R. Getzenberg, M.M. Markowski, et al. · European Urology Supplements

Works count: 7

Citation count: 38

H-index: 3

I10-index: 1